Clear Labs harnesses the power of next-generation sequencing (NGS) to simplify complex genomics applications. By providing a flexible, scalable and fully automated platform that integrates DNA sequencing, robotics, and cloud-based bioinformatics and analytics, Clear Labs is making genomics accessible to all with faster turnaround time to aid decision-making, reduced operational cost and ultimately, better health outcomes for all.
ChemPartner
Over the past twenty years, ChemPartner has evolved from a pure chemistry service provider to a research innovation engine with a broad portfolio of services spanning from discovery through development in both small molecule and large molecule therapeutics.
Charles River
Charles River is a global preclinical oncology CRO delivering end to end oncology and immuno oncology drug discovery, from target identification and validation through IND enabling and clinical. We partner with academic, biotechnology, and pharmaceutical companies to advance innovative cancer therapies. In 2025, Charles River supported 87% of FDA-approved oncology therapies, including first-in-class and best-in-class drugs. Our capabilities span small molecules, biologics, antibodies, antibody drug conjugates (ADCs), immunotherapies, checkpoint inhibitors, cell therapies, and gene therapies. Our research model (RMS) portfolio includes immunodeficient mice and rats, PBMC and CD34+ humanized mouse models, end-to-end support from colony management for Genetically Engineered Model (GEM), including transgenic model generation and breeding, to vivarium rental or customizable onsite services (staffing, consulting, training), and CRADL® support in global biohubs. Our oncology platforms include 1,700+ xenograft models (PDX, CDX, syngeneic, humanized), covering 45+ cancer indications across solid tumors, hematologic, and pediatric cancers. Integrated in vitro, ex vivo, NAMs and 3D tumor models—including organoids, tumoroids, and tissue microarrays (TMAs)- support efficacy, PK/PD, biomarker, and translational decision making. Multi omics, AI enabled analytics, and strategic CMC/CDMO capabilities help teams plan manufacturing earlier, strengthen regulatory readiness, improve study design, reduce risk, and accelerate candidate to patients. Learn more at criver.com/cancer-research-annual-meeting-2026 | Charles River has supported researchers in advancing ocular therapies for more than two decades, with a comprehensive suite of capabilities designed to meet your program needs. We help you progress small molecules, biologics, gene and cell therapies, and implantable devices from concept to clinic with confidence. Our team provides rigorous efficacy, distribution, and safety assessments supported by state-of-the-art imaging, functional evaluations, and New Approach Methodologies (NAMs) to help you improve predictability and generate high-quality data for global regulatory submissions. We also assess the ocular effects of systemic compounds for non-ocular indications, helping you refine study design, manage timelines and resources, and reduce animal use. We are committed to partnering with you at every stage to help bring meaningful treatments to patients worldwide because every moment matters. | Charles River provides essential products and services to support pharmaceutical and biotechnology companies, government agencies, and leading academic institutions worldwide in accelerating research and drug development. As a leader in scientific innovation, we are deeply committed to pioneering alternative methods that drive discovery while reducing reliance on traditional models. By embracing cutting-edge technologies and forward-thinking approaches, we enhance preclinical and clinical research. Our dedicated employees focus on delivering precisely what our clients need to improve, innovate, and expedite the discovery, early-stage development, and safe manufacture of new therapies for patients—because every moment matters. Learn more at www.criver.com. | Charles River is committed to helping companies like yours get your product to market safely and efficiently. Whether you’re still in development or already manufacturing, our Safety Assessment and Microbial Solutions services provide state-of-the-art technology and expert regulatory advice that will help you anticipate challenges, avoid roadblocks, and make better decisions.
Celnovte Biotechnology
Celnovte Biotechnology is a leading innovator in the field of biotechnology, dedicated to advancing immunohistochemistry (IHC), molecular pathology, and hematology research and diagnostics. With cutting-edge technology and rigorous scientific development, we deliver high-quality, reliable solutions that empower laboratories worldwide. Our product portfolio includes: • Advanced multiplex IHC (mIHC) kits featuring proprietary fluorescent markers for comprehensive tissue analysis. • Robust secondary antibodies designed for enhanced specificity and minimal background. • State-of-the-art ISH technologies, including CISH and FISH, for superior hybridization accuracy. • User-friendly automated staining platforms compatible with industry-standard systems. Celnovte is committed to meeting the evolving needs of researchers and clinicians by providing innovative tools that streamline workflows and ensure precision. With a strong focus on customer collaboration, we aim to foster advancements in life sciences, contributing to groundbreaking discoveries and better healthcare outcomes.
Cellecta, Inc.
Cellecta is a trusted provider of functional genomic products and services, offering loss-of-function and gain-of-function CRISPR & RNAi screening, cell barcoding and immune receptor and targeted RNA-Seq expression profiling. We design and manufacture CRISPR, RNAi and cell barcode libraries, kits for immune repertoire and gene expression profiling, lentiviral constructs, and offer cell engineering services for drug target and biomarker discovery.
Cell Signaling Technology
CST® is a privately-owned, global company headquartered in Danvers, Mass., USA. Founded in 1999 and still led by research scientists. We are actively engaged in the development of products and technologies that facilitate signaling analysis and mechanistic cell biology and cancer research.
Calbiotech, Inc.
Calbiotech is a San Diego-based company specializing in contract development and manufacturing for diagnostic and life science applications. We support partners across regulated and RUO programs through tech transfer, custom development, and scalable production—delivering flexible, high-quality solutions at every stage. FDA- and USDA-licensed facilities operating under ISO 13485:2016 and cGMP standards Supplying 300+ products to partners in the U.S. and 70+ countries for RUO and clinical use Produced over 15 million tests in 2024 across contract and in-house manufacturing programs Active pipeline across Immunoassay, Microarray, Molecular, and POC assay formats Expanding portfolio of contract development and manufacturing projects across RUO, LDT, and IVD Flexible support from pilot-scale development to full-scale commercialization The Calbiotech Group includes specialized entities supporting regulated manufacturing, antigen production, and automated liquid handling—enabling faster, integrated development for our partners.
Burning Rock Dx LLC
Burning Rock Dx (NASDAQ: BNR) is a global diagnostics company focusing on applying next-generation sequencing (NGS) technology in precision oncology. Guided by the mission of “Guard Life via Science,” Burning Rock offers solutions covering the entire precision oncology development cycle through an internally developed NGS-based assay portfolio for both tissue and blood samples, along with a robust in-house database to help facilitate clinical trial studies and research. Burning Rock provides dedicated services to pharmaceutical partners, encompassing genomic data solutions, clinical trial solutions, precision patient recruitment, and companion diagnostics (CDx) development and commercialization. Burning Rock’s diverse portfolio operates out of their two CLIA/CAP laboratories in China and the United States, allowing for global clinical trial support. Burning Rock has achieved two NMPA-approved IVD kits, four assays with CE marking, and a breakthrough device designation (BDD) received from both US FDA and China NMPA for multi-cancer detection blood test. Leveraging their robust NGS technology and extensive experience in pharmaceutical and project partnerships, Burning Rock stands as a global collaborator in driving advancements in precision oncology.
Bruker Spatial Biology
Bruker Spatial Biology, a division of Bruker Corporation, provides advanced spatial molecular biology solutions, including instruments, assays, software, and services to support life sciences research. By integrating technologies from NanoString and Canopy Biosciences, Bruker offers an extensive portfolio designed to meet the diverse needs of global researchers exploring spatial biology. The CosMx® Spatial Molecular Imager (SMI) enables high-plex detection and analysis of over 6,000 RNAs with single-cell resolution and precise cell segmentation, supported by the cloud-based AtoMx™ Spatial Informatics Platform. The GeoMx® Digital Spatial Profiler is a leading platform for whole-tissue exploration, providing whole transcriptomics and high-plex proteomic readouts. The CellScape™ Precise Spatial Proteomics platform allows for high-plex protein expression analysis at single-cell resolution, using versatile, open-sourced reagents. The nCounter® Analysis System enables rapid quantification of profiling of gene and miRNA expression with high sensitivity. Together, Bruker Spatial Biology’s solutions are supported by a strong team of scientists, sales, and service associates, along with Canopy Multiomic Services for biopharmaceutical research, assay development, and clinical sample testing.
Boster Biological Technology
Boster Bio is a leading provider of high-quality antibodies and ELISA kits trusted by researchers worldwide for their reliability, consistency, and scientific rigor. For more than two decades, our mission has been to empower life science discovery by delivering reagents and services that produce reproducible, publication-grade results across immunology, neuroscience, oncology, and developmental biology. Our antibody and ELISA portfolio is built on stringent quality standards, including comprehensive validation and application-specific testing to ensure that every product performs as expected in the laboratory. Scientists rely on Boster Bio not only for dependable reagents but also for our responsive technical support and commitment to helping customers achieve clarity in complex biological systems. As research needs evolve, we continue to innovate. Our multiplex immunofluorescence staining solutions enable deeper, more efficient tissue analysis, providing powerful insights into cell-type interactions, biomarker localization, and disease mechanisms. By integrating advanced staining technologies with expert scientific guidance, we help teams accelerate decision-making and reduce experimental uncertainty. Across academia, biotech, and pharmaceutical R&D, Boster Bio is recognized as a trusted partner delivering high-quality reagents, innovative tools, and unwavering support. We remain dedicated to driving scientific progress through precision, performance, and customer-centered service.